Clinical Trial Detail

NCT ID NCT02665650
Title Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Affimed GmbH
Indications

Hodgkin's lymphoma

Therapies

AFM13 + Pembrolizumab

Age Groups: adult

Additional content available in CKB BOOST